Portable insulin pumps are a safe and valuable treatment option for patients with type 2 diabetes whose glycaemic control using conventional insulin injections is inadequate, say the authors of the newly published OpT2mise trial
After six months, glycated haemoglobin (HbA1c) declined by 1.1%, on average, in a study of 168 people randomly assigned to use an insulin pump and by 0.4% in 163 subjects who continued with multiple daily insulin injections.
Those using the pump were also more likely to achieve their HbA1c target, less likely to be either hypo- or hyperglycaemic, and used a lower daily insulin dose.
The study is published in
 Reznik Y et al. The Lancet [online] doi 10.1016/S0140-6736(14)61037-0.